Professor Myers' research program involves the synthesis and study of complex molecules of importance in biology and human medicine. His group has developed laboratory synthetic routes to a broad array of complex natural products, including the ene-diyne antibiotics neocarzinostatin chromophore, dynemicin A, N1999A2, and kedarcidin chromophore, undertakings greatly complicated by the chemical instability of all members of the class. His laboratory developed the first practical synthetic route to the tetracycline antibiotics, allowing for the synthesis of more than three thousand fully synthetic analogs (compounds inaccessible by semi-synthesis: chemical modification of natural products) by a scalable process. A portfolio of clinical candidates for the treatment of infectious diseases, all fully synthetic tetracycline analogs, are currently in development at Tetraphase Pharmaceuticals, a company founded by Myers. In addition, the Myers' laboratory has developed short, practical and scalable synthetic routes to the saframycin, cytochalasin, stephacidin B-avrainvillamide, and trioxacarin classes of natural antiproliferative agents, in each case by the modular assembly of simple components of similar synthetic complexity. His group has reported synthetic routes to the natural products epoxybasmenone, cyanocycline, terpestacin, salinosporamides, and cortistatins A, J, K, and L. Increasingly, the Myers' laboratory is dedicated to the development of highly convergent synthetic pathways that (1) provide practical, scalable solutions for the construction of molecular classes multiplicatively expanded by (2) incorporation of modular variations.